Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Not Yet Opened 10-08 16:00:00 EDT

22.21

-0.52

-2.29%

盘后22.21

+0.000.00%

19:30 EDT

High22.60	Low21.55	Vol2.34M
Open22.49	D1 Closing22.73	Amplitude4.62%
Mkt Cap2.30B	Tradable Cap1.65B	Total Shares103.41M
T/O51.78M	T/O Rate3.16%	Tradable Shares74.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":22.21,"timestamp":1791489600000,"preClose":22.73,"halted":0,"volume":2344973,"hourTrading":{"tag":"盘后","latestPrice":22.21,"preClose":22.21,"latestTime":"19:30 EDT","volume":240583,"amount":5343919.0232,"timestamp":1791502204131,"change":0,"changeRate":0,"amplitude":0.028379},"delay":0,"changeRate":-0.022877254729432448,"floatShares":74111900,"shares":103405813,"eps":-3.410201,"marketStatus":"Not Yet Opened","change":-0.52,"latestTime":"10-08 16:00:00 EDT","open":22.49,"high":22.6,"low":21.55,"amount":51778192.741311,"amplitude":0.046194,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.410201,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":0,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":22.73,"preHourTrading":{"tag":"盘前","latestPrice":22.43,"preClose":22.73,"latestTime":"09:29 EDT","volume":1280,"amount":28914.944,"timestamp":1791466199999,"change":-0.3,"changeRate":-0.013198,"amplitude":0.051087},"postHourTrading":{"tag":"盘后","latestPrice":22.21,"preClose":22.21,"latestTime":"19:30 EDT","volume":240583,"amount":5343919.0232,"timestamp":1791502204131,"change":0,"changeRate":0,"amplitude":0.028379},"volumeRatio":1.972904,"impliedVol":0.9246,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/NRIX/","defaultTab":"news","newsList":[{"id":"2674088087","title":"Nurix Therapeutics (NRIX) Starts New CLL Trial, Is The 11% Discount Warranted?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674088087","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674088087?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:37","pubTimestamp":1791513449,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has enrolled the first patient in its Phase 1b/2 NX-5948-203 trial, which pairs its BTK degrader bexobrutideg with venetoclax for chronic lymphocytic leukemia as part of a broader collaboration with Roche.\nNurix Therapeutics’ recent headlines around its Roche and Gilead collaborations come against a mixed trading backdrop, with the share price down 15.0% over the past month but still showing a 22.98% year to date share price return and a 104.51% total shareholder...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-new-cll-trial-is-the-11-disco","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-new-cll-trial-is-the-11-disco","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674001259","title":"Nurix Therapeutics options imply 4.5% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2674001259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674001259?lang=en_us&edition=fundamental","pubTime":"2026-10-09 01:05","pubTimestamp":1791479113,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Nurix Therapeutics (NRIX) is normal with puts leading calls 3:2. Implied volatility suggests the market is anticipat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-options-imply-4-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-options-imply-4-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGLO","DECU","JOYT","PMDE","VOTE","NRIX","GXDW","FEBU","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673001724","title":"U.S. Earnings Preview: After Market Close Oct. 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2673001724","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673001724?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:30","pubTimestamp":1791401400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results after the market closes.Levi Strauss & Co.'s third-quarter EPS is forecast at 36 cents.Applied Digital Corp.'s first-quarter EPS is forecast at a loss of 30 cents, compared with a loss of 7 cents in the prior-year period.Nurix Therapeutics Inc.'s third-quarter EPS is forecast at a loss of 60 cents, compared with a loss of $1.03 in the prior-year period.Richardson Electronics Ltd.'s first-quarter EPS is forecast at 9 cents, compared with 13 cents in the prior-year period.Resources Connection Inc.'s first-quarter EPS is forecast at a loss of 20 cents, compared with a loss of 7 cents in the prior-year period. Adjusted EPS is forecast at a loss of 17 cents.Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLD","BK4023","MNRS","FDIG","BK4202","DAPP","APLZ","RELL","LU1815336091.USD","LU0757428866.USD","APLX","IBLC","NRIX","BK4609","LEVI","BK4140","BK4139","BK4123","BK4608","BK4116","RGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673060636","title":"Nurix Enrolls First Patient in Phase 1b/2 CLL Trial of BTK Degrader Bexobrutideg Plus Venetoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2673060636","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673060636?lang=en_us&edition=fundamental","pubTime":"2026-10-07 13:00","pubTimestamp":1791349216,"startTime":"0","endTime":"0","summary":"Nurix enrolls first patient in Phase 1b/2 CLL trial of BTK degrader bexobrutideg plus venetoclaxNurix enrolled the first patient in a Phase 1b/2 study testing BTK degrader bexobrutideg with venetoclax","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDLTbkV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","NRIX","LU0314104364.USD","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112","BK4139","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673060689","title":"Nurix Therapeutics Announces First Patient Enrolled in Phase 1B/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673060689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673060689?lang=en_us&edition=fundamental","pubTime":"2026-10-07 13:00","pubTimestamp":1791349200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUA47GW9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704303","title":"Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704303","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704303?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:03","pubTimestamp":1791198202,"startTime":"0","endTime":"0","summary":"Nurix, Gilead extend research term for oncology program by two years for $10 million feeNurix Therapeutics extended the research term for an undisclosed oncology program under its strategic collaborat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL7nTmpm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0965509283.SGD","IBB","LU1430594728.SGD","LU1934455194.USD","BIB","LU1066051498.USD","IE0002270589.USD","LU0965509101.SGD","NDAQ","BBH","LU1839511570.USD","LU0320765992.SGD","IE00BQXX3D17.EUR","BK4583","IE00BQXX3F31.USD","SG9999015945.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU1934455277.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","SG9999015986.USD","BCDF","LU2210150020.SGD","LU0058720904.USD","BK4585","BK4112","BK4568","LU0314104364.USD","LU0965509010.AUD","BMED","GILD","NRIX","SG9999015978.USD","BK4578","TBXU","LU1037948541.HKD","LU0882574055.USD","LU0861579265.USD","LU1057294990.SGD","IE00BN0W2W23.USD","LU0109394709.USD","TMED","LU0859254822.USD","SG9999014021.USD","MEDI","LU1037948897.HKD","LU2087621335.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704306","title":"Nurix Extends Gilead Collaboration for Oncology Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704306","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704306?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:03","pubTimestamp":1791198199,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Extends Gilead Collaboration For Oncology ProgramOct 5 (Reuters)-Nurix Therapeutics, Inc.NRIX.O:NURIX THERAPEUTICS ANNOUNCES SECOND RESEARCH TERM EXTENSION FOR ONCOLOGY PROGRAM UNDER COLLA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","BK4566","SG9999015978.USD","BK4550","IE00B19Z3B42.SGD","LU0859254822.USD","LU2468319806.SGD","LU1066053197.SGD","IBBQ","LU0861579265.USD","LU0965509101.SGD","IE00BKVL7J92.USD","LU0122379950.USD","LU1934455277.USD","LU1934455863.HKD","LU2087621335.USD","LU1839511570.USD","BK4139","LU2089984988.USD","LU1057294990.SGD","SG9999015945.SGD","LU1674673691.USD","TBXU","BIB","LU0320765992.SGD","LU0965508806.USD","MEDI","LU0058720904.USD","LU1585245621.USD","BK4568","BBH","LU2357627491.SGD","IBB","LU1023059063.AUD","LU0882574055.USD","GILD","LU1037948897.HKD","LU1934455194.USD","TMED","NRIX","LU1571399168.USD","IE00B7SZLL34.SGD","LU0965509010.AUD","LU2324357040.USD","SG9999015952.SGD","LU0965509283.SGD","IE00B3T34201.USD","BMED","LU0109394709.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704828","title":"Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704828?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","LU2089984988.USD","BK4139","IBBQ","LU0965509283.SGD","IBB","LU1934455194.USD","BIB","LU1061106388.HKD","LU1585245621.USD","BBH","LU1839511570.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4583","IE00BKVL7J92.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1778281490.HKD","LU1934455277.USD","LU1066053197.SGD","LU1023059063.AUD","LU2112291526.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0122379950.USD","BK4568","LU0114720955.EUR","BMED","GILD","BK4532","NRIX","SG9999015978.USD","BK4578","TBXU","BK4588","LU0882574055.USD","LU0861579265.USD","LU0823416689.USD","TMED","LU0859254822.USD","LU1571399168.USD","MEDI","IE00B7SZLL34.SGD","BK4550","LU1037948897.HKD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673701023","title":"Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673701023","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673701023?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048487","title":"Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048487?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","GILD","IE00BKVL7J92.USD","LU1057294990.SGD","SG9999015986.USD","LU0823416689.USD","LU0889565916.HKD","TBXU","BMED","LU0965509283.SGD","LU1934455194.USD","BK4568","LU1778281490.HKD","IE00B19Z3B42.SGD","LU0861579265.USD","SG9999015952.SGD","LU1430594728.SGD","LU1037948541.HKD","LU0965509010.AUD","LU1066051498.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","BK4566","LU0859254822.USD","IE0002270589.USD","LU0122379950.USD","LU0234570918.USD","IBB","LU1023059063.AUD","MEDI","LU2089984988.USD","BIB","TMED","LU0320765992.SGD","IBBQ","LU1839511570.USD","IE00BSNM7G36.USD","LU0965509101.SGD","LU2468319806.SGD","LU1571399168.USD","IE00B3T34201.USD","LU1934455863.HKD","LU1066053197.SGD","NRIX","BK4550","LU0289739699.SGD","SG9999015945.SGD","LU2087621335.USD","LU1037948897.HKD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048127","title":"Nurix - to Receive $10 Mln Research Term Extension Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048127?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBBQ","BK4566","LU0823416689.USD","LU2468319806.SGD","IE00B3T34201.USD","LU1037948541.HKD","LU1839511570.USD","MEDI","LU0289739699.SGD","BIB","LU2087621335.USD","LU0320765992.SGD","BK4568","LU0965509101.SGD","LU0122379950.USD","BMED","IE00BSNM7G36.USD","LU0965509283.SGD","BK4550","LU0234570918.USD","LU0859254822.USD","LU1674673428.USD","LU1778281490.HKD","TMED","LU0965509010.AUD","LU0861579265.USD","SG9999015952.SGD","IBB","SG9999015945.SGD","TBXU","LU1037948897.HKD","GILD","LU1066053197.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1430594728.SGD","NRIX","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","SG9999015986.USD","LU1066051498.USD","BBH","LU1934455863.HKD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1023059063.AUD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1934455194.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673021701","title":"Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2673021701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673021701?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","GILD","LU1057294990.SGD","SG9999015986.USD","LU0889565916.HKD","TBXU","BMED","LU0965509283.SGD","LU1934455194.USD","BK4568","LU1778281490.HKD","BK4532","LU0882574055.USD","IE00B19Z3B42.SGD","LU0861579265.USD","LU1430594728.SGD","LU1037948541.HKD","LU0965509010.AUD","LU1066051498.USD","BK4583","IE00BZ1G4Q59.USD","BK4566","LU0859254822.USD","IE0002270589.USD","LU0122379950.USD","LU1061106388.HKD","IBB","MEDI","BIB","LU0058720904.USD","TMED","LU0320765992.SGD","IBBQ","BK4578","LU1839511570.USD","LU1934455277.USD","IE00BSNM7G36.USD","LU0965509101.SGD","LU2468319806.SGD","LU1571399168.USD","IE00B3T34201.USD","LU1066053197.SGD","NRIX","LU0289739699.SGD","BK4585","LU0109394709.USD","SG9999015945.SGD","LU2087621335.USD","LU1037948897.HKD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672974168","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Common Share Disposal Worth $134,160.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974168","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974168?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:21","pubTimestamp":1790976098,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring reports common share disposal worth $134,160.79Christine Ring, Chief Legal Officer at Nurix Therapeutics, sold 5,786 common shares on Oct. 2, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL4qM4kv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Common Share Disposal Worth $134,160.79","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671157692","title":"Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671157692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671157692?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA42HKSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","LU0234572021.USD","LU1883839398.USD","BK4592","IE0002270589.USD","BK4007","LU0058720904.USD","IE00BLSP4239.USD","LU0456855351.SGD","LU1894683264.USD","IE00BLSP4452.SGD","BK4139","IE000M9KFDE8.USD","LU1066053197.SGD","BK4599","LU0225284248.USD","IE00B19Z3B42.SGD","PFE","SG9999002232.USD","BK4534","LU0225771236.USD","BK4581","IE00B19Z3581.USD","LU0868494617.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0122379950.USD","LU0306807586.USD","LU0170899867.USD","LU1066051498.USD","SG9999011175.SGD","BK4550","LU0321505439.SGD","BK4533","SG9999001176.SGD","BK4585","IE00BBT3K403.USD","LU0289739699.SGD","LU2596442595.SGD","BK4588","SG9999001176.USD","LU0306806265.USD","SG9999003800.SGD","LU1894683348.USD","SGXZ57979304.SGD","LU0321505868.SGD","BK4568","LU1023059063.AUD","NRIX","SG9999013999.USD","SG9999002224.SGD","LU0985481810.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664619508","title":"Nurix CSO Gwenn Hansen Disposes of 1,452 Common Shares Worth $36,982.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2664619508","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664619508?lang=en_us&edition=fundamental","pubTime":"2026-09-02 05:19","pubTimestamp":1788297598,"startTime":"0","endTime":"0","summary":"Nurix CSO Gwenn Hansen disposes of 1,452 common shares worth $36,982.44Nurix Therapeutics Chief Scientific Officer Gwenn Hansen exercised employee stock options for 1,452 shares at USD 1.86 on Sept. 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3dpqSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix CSO Gwenn Hansen Disposes of 1,452 Common Shares Worth $36,982.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664562658","title":"Nurix Therapeutics to Participate in Upcoming September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664562658","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664562658?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354077/0/en/nurix-therapeutics-to-participate-in-upcoming-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097223","title":"Nurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIX","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097223","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663097223?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:31","pubTimestamp":1787934694,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. The Phase 1b/2 study “An Open-label, Multicenter Phase 1b/2 S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nurix-advances-nx-5948-combo-trial-in-b-cell-cancers-setting-up-key-catalyst-for-nrix?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nurix-advances-nx-5948-combo-trial-in-b-cell-cancers-setting-up-key-catalyst-for-nrix?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175580","title":"BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175580","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175580?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:12","pubTimestamp":1787670744,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  BTK degrader tacabrutideg presents a \"sizable opportunity\" in chronic spontaneous urticaria or CSU, RBC Capital Markets said in a Tuesday note.CSU is an inflammatory skin condition that can be a major market with peak sales estimates of about $3 billion, the brokerage said. BTK degraders have the potential to top BTK inhibitors in CSU, likely exceeding inhibitors in terms of potency and effect durability, RBC noted.Nurix Therapeutics  has reported that its BTK degrader bexobrutideg demonstrated greater potency in CSU compared with Novartis'  BTK inhibitor remibrutinib, and RBC sees tacabrutideg's overall efficacy profile as \"broadly comparable\" with bexobrutideg, according to the note.BeOne Medicines is planning to advance tacabrutideg to phase 2 studies in CSU, RBC noted.RBC has an outperform rating and $450 price target on BeOne Medicines.Price: 376.42, Change: +4.44, Percent Change: +1.19","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0070302665.USD","BK4588","PPH","LU0211331839.USD","BK4007","NVS","ONC","BK4139","IE00BFTCPJ56.SGD","BK4585","BK4532","BK4578","MEDX","IE00B4R5TH58.HKD","MDCO","IE00BJT1NW94.SGD","LU0320765489.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","NRIX","IE0002141913.USD","LU0208291251.USD","BK4526","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660863842","title":"Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660863842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660863842?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUA4NZZHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456397","title":"Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456397","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456397?lang=en_us&edition=fundamental","pubTime":"2026-08-18 09:23","pubTimestamp":1787016212,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has drawn investor attention after two key events. The company reported a new Phase 3 trial for its BTK degrader bexobrutideg and a separate US$10 million milestone payment from collaborator Sanofi.\nSee our latest analysis for Nurix Therapeutics.\nAgainst this backdrop, Nurix Therapeutics’ recent clinical milestones and collaboration progress have coincided with strong momentum, with a 30 day share price return of 17.52% and a 1 year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-phase-3-and-lands-sanofi-mile","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-phase-3-and-lands-sanofi-mile","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX","BK4139","SNYNF","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0484},{"period":"1month","weight":-0.15},{"period":"3month","weight":-0.0369},{"period":"6month","weight":0.3855},{"period":"1year","weight":1.2255},{"period":"ytd","weight":0.1708}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.5,"avgChangeRate":0.009892},{"month":6,"riseRate":0.666667,"avgChangeRate":0.159386},{"month":7,"riseRate":0.5,"avgChangeRate":0.064005},{"month":8,"riseRate":0.571429,"avgChangeRate":0.029558},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.003382},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.00569},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction